AI assistant
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2022
Dec 21, 2022
31071_dirs_2022-12-20_2f390e07-bc3c-4805-8c5c-d41edd60f229.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2022-12-16
Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-16 | Common Stock | A | 18375 | $0.00 | Acquired | 3486689 | Direct |
| 2022-12-20 | Common Stock | A | 234025 | $0.00 | Acquired | 3720714 | Direct |
Footnotes
F1: Represents shares of stock which vested on the date of issuance.
F2: Includes 93,610 shares underlying restricted stock units, which will vest in four equal installments, with a commencement date of 12/20/22. Includes 140,415 underlying restricted stock units, that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part of in whole.
F3: Includes a total of 1,789,697 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.